Veckenstedt A
Acta Virol. 1978 Jan;22(1):52-9.
3-[Bis-(2-hydroxyethyl)-amino]-acetophenone-[4.5-diphenyl-oxazolyl-(2)]-hydrazone (IMET 98/69) was found to afford maximum "rates of protection" in intraperitoneally (i.p.) or intranasally (i.n.) induced Mengo virus encephalitis in mice when administered once daily at doses of 1 mmole/kg (456.5 mg/kg) subcutaneously (s.c.) or 4 mmoles/kg (1 826 mg/kg) perorally (p.o.). Three days of treatment were sufficient if started on the day before or at the time of virus inoculation. Initiation of treatment 6 hours after inoculation was no longer effective. In a remarkable number of brains from infected and treated mice no virus was detectable, while in the remaining brains the appearance of virus was strongly delayed, and its amount significantly reduced.
3-[双-(2-羟乙基)-氨基]-苯乙酮-[4,5-二苯基-恶唑基-(2)]-腙(IMET 98/69)被发现,当以1毫摩尔/千克(456.5毫克/千克)的剂量皮下注射或4毫摩尔/千克(1826毫克/千克)的剂量口服,每日给药一次时,对小鼠腹腔内或鼻内感染的门戈病毒脑炎能提供最大的“保护率”。如果在病毒接种前一天或接种时开始治疗,三天的治疗就足够了。接种后6小时开始治疗不再有效。在大量感染并接受治疗的小鼠大脑中检测不到病毒,而在其余大脑中,病毒的出现被强烈延迟,其数量显著减少。